Article Information
PMID
Published By
Print ISSN
0250-7005
Online ISSN
1791-7530
History
- Received August 31, 2012
- Revision received October 11, 2012
- Accepted October 12, 2012
- Published online December 6, 2012.
Copyright & Usage
Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
Author Information
- MARC GIGANTE1,*⇓,
- GUORONG LI1,*,
- CELINE FERLAY3,
- DAVID PEROL3,
- ELLEN BLANC3,
- STEPHANE PAUL2,
- AN ZHAO2,
- JACQUES TOSTAIN1,
- BERNARD ESCUDIER4,
- SYLVIE NEGRIER3 and
- CHRISTIAN GENIN2
- 1Department of Urology, University of Jean Monnet, Saint-Etienne, France
- 2Immunology Laboratory, CHU of Saint-Etienne, University of Jean Monnet, Saint-Etienne, France
- 3Léon Bérard Center, University of Lyon, Lyon, France
- 4Gustave Roussy Institute, Villejuif, France
- Correspondence to: Dr. Marc Gigante, Department of Urology and Kidney Transplantation, CHU La Réunion, 97405 Saint Denis cedex, La Réunion, France. Tel: +33 262905461, Fax: +33 262905462, e-mail: marc.gigante{at}chu-reunion.fr
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
- The Utility of Serum CA9 for Prognostication in Prostate Cancer
- Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy